|
T1752 |
NS6180
|
|
Potassium Channel
|
|
NS6180 is a potent and selective KCa3.1 channel inhibitor(IC50= 9 nM). It prevents T-cell activation and inflammation. |
|
T4084 |
Sibofimloc
|
VRT-1353385,Antibiotic-202,Antibiotic 202 |
Antibacterial
,
Antibiotic
|
|
Sibofimloc (Antibiotic-202), an antibiotic compound, is used in treating bacterial infections. |
|
T2601 |
Vidofludimus
|
SC12267,4sc-101 |
Dehydrogenase
,
DNA/RNA Synthesis
,
Interleukin
|
|
Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). |
|
T24997 |
ABT-510 acetate
|
ABT 510 acetate |
Apoptosis
|
|
ABT-510 acetate is an endogenous anti-angiogenic TSP peptide inhibitor, a thrombospondin analog, with anti-inflammatory, anti-cancer and anti-angiogenic activity that induces apoptosis and inhibits ovarian tumor growth i... |
|
T79600 |
Zharp2-1
|
|
RIP kinase
|
|
Zharp2-1, a RIPK2 inhibitor, inhibits the transcription of inflammatory cytokines induced by MDP-induced or Listeria monocytogenes infection and alleviates MDP-induced peritonitis symptoms in mice, which can be used for ... |
|
T9975 |
GPR183
|
3-(3,4-difluorophenyl)-N-[3-fluoro-5-(morpholin-4-yl)phenyl]propanamide |
Others
|
|
GPR183 (3-(3,4-difluorophenyl)-N-[3-fluoro-5-(morpholin-4-yl)phenyl]propanamide) is a chemotactic receptor known for its role in the maturation of B cells, and the endogenous ligand is the oxysterol 7α,25-dihydroxycholes... |
|
T38944 |
Tetomilast
|
OPC-6535,Tetomilast |
|
|
Tetomilast (OPC-6535) is a phosphodiesterase-4 (PDE4) inhibitor, potentially effective in treating inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). |
|
T62462 |
RORγt/DHODH-IN-2
|
|
|
|
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor that can be used in the study of inflammatory bowel disease (IBD). |
|
T7749 |
ALB-127158
|
|
|
|
ALB-127158(a) is a potent and selective melanin concentrating hormone 1 ( MCH 1 ) receptor antagonist which may be a potential treatment for inflammatory bowel disease (IBD). |
|
T76737 |
Abrilumab
|
|
|
|
Abrilumab, a fully human monoclonal antibody, targets the α4β7 integrin heterodimer, selectively binding to it. This specificity makes it a potential research tool for investigating inflammatory bowel disease (IBD) [1]. |
|
T82223 |
HDHODH-IN-13
|
|
|
|
hDHODH-IN-13 (compound w2), an inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibits an IC50 of 173.4 nM and has potential research applications in studying inflammatory bowel disease (IBD) [1]. |
|
T76056 |
Glepaglutide
|
|
|
|
Glepaglutide (ZP1848), a long-acting glucagon-like peptide-2 (GLP-2) analogue, functions as a potent agonist of the GLP-2 receptor (GLP-2R), effectively reducing fecal output and enhancing intestinal absorption, while al... |
|
T79385 |
PDE1-IN-5
|
|
|
|
PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor with an IC50 of 15 nM, exhibiting anti-inflammatory properties through the inhibition of iNOS, TNF-α, IL-1α, IL-1β, and IL-6 expression induced by LPS. It has demon... |
|
T76057 |
Glepaglutide acetate
|
|
|
|
Glepaglutide (ZP1848) acetate is a long-acting glucagon-like peptide-2 (GLP-2) analogue and a potent GLP-2 receptor (GLP-2R) agonist. It significantly reduces fecal output and enhances intestinal absorption while also mi... |
|
T79527 |
BET BD2-IN-1
|
|
Epigenetic Reader Domain
|
|
BET BD2-IN-1 (compound 45) is a potent, selective inhibitor of BET BD2, exhibiting an IC50 value of 1.6 nM. It suppresses Th17 cell differentiation through the reduced activation of STAT3 and NF-κB, making it relevant in... |
|
T77154 |
Etrolizumab
|
|
|
|
Etrolizumab (rhuMAb Beta7), a gut-selective anti-β7 integrin monoclonal antibody, targets the β7 subunit of α4β7 and αEβ7 integrins specifically, demonstrating affinity with K i values of 18 nM for Human α4β7 and 1800 pM... |
|
T70899 |
Vidofludimus hemicalcium
|
4sc-101 hemicalcium,SC12267 hemicalcium,4sc-101 hemicalcium ; SC12267 hemicalcium |
|
|
Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulat... |
|
T62556 |
JAK-IN-23
|
|
|
|
JAK-IN-23 is an orally active dual JAK/STAT and NF-κB inhibitor that inhibits J AK1 (IC50: 8.9 nM), J AK2 (IC50: 15 nM), and J AK3 (IC50: 46.2 nM). JAK-IN-23 exhibits strong anti-inflammatory effects and can reduce the r... |
|
T78084 |
PSB 0777 ammonium hydrate
|
|
Adenosine Receptor
|
|
PSB 0777 ammonium hydrate is a potent and selective adenosine A2A receptor full agonist, exhibiting K i values of 44.4 nM for rat A2A receptors and 360 nM for human A2A receptors. For rat and human A1 receptors, it shows... |
|
T36660 |
Olsalazine-13C6
|
Olsalazine-13C6 |
|
|
Olsalazine-13C6is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that... |
